Clinical and biochemical markers of joint damage in patients with diabetes mellitus

Authors

  • V. L. Orlenko SI “V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”, Kyiv,
  • M. D. Tronko SI “V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”, Kyiv, Academician of the NAS of Ukraine,

DOI:

https://doi.org/10.14739/2310-1210.2020.3.204896

Keywords:

diabetes mellitus, diabetic arthropathy, joints, chondrocytes, insulin

Abstract

 

The aim of our work was to study the COMP level in the blood serum of patients with type 1 and type 2 diabetes with arthropathy and to determine the relationship with functional indices characterizing the clinical manifestations of joint damage in patients with diabetes mellitus.

Materials and methods. The study involved 87 patients (35 men and 52 women) with diabetes. Patients were divided into groups depending on the type of diabetes and the presence of arthropathy. Patients were examined using a visual analogue scale, Lequesne’s index and WOMAC scale. Cartilage oligomeric matrix protein (COMP) was determined by enzyme immunoassay.

Results. The presence of diabetic arthropathy was found in 78 % of patients with type 1 diabetes and in 80 % of patients with type 2 diabetes. In the vast majority of patients (20 with type 1 diabetes and 30 with type 2 diabetes), the joints of the upper extremities were involved in the pathological process. We found an increase in functional indices in patients with arthropathy in both types of disease: Lequesne’s index – t = -5.5, P = 0.001 – in patients with type 1 diabetes, t = -6.9, P = 0.001 – in patients with type 2 diabetes, WOMAK index (t = -5.4, P = 0.001), (t = -7.8, P = 0.001); visual analogue scale (t = -6, P = 0.001), (t = -6.9, P = 0.001), respectively. Average COMR values significantly increased with the arthropathy stage progression (t = -3.4, P = 0.005; t = -2.4, P = 0.0023; t = -3.2, P = 0.006) in patients with type 1 diabetes. In patients with type 2 diabetes, the significance of differences was found between the control group and patients with stage 1 (t = 3.4, P = 0.001), between stages 1 and 2 (t = -4.1, P = 0.001). A direct correlation was established between the presence of arthropathy and the COMP level (r = 0.76, P = 0.001), between the presence of arthropathy and the Lequesne’s index (r = 0.76, P = 0.001), the visual analogue scale (r = 0.88, P = 0.001) and WOMAC (R = 0.88, P = 0.001).

Conclusions. The results suggest that arthropathy in patients with type 1 and type 2 diabetes is characterized by an increase in the cartilage degradation marker directly related to the severity and the number of joints affected.

References

Yan, W., & Li, X. (2013). Impact of diabetes and its treatments on skeletal diseases. Frontiers of Medicine, 7(1), 81-90. https://doi.org/10.1007/s11684-013-0243-9

Schett, G., Kleyer, A., Perricone, C., Sahinbegovic, E., Iagnocco, A., Zwerina, J., Lorenzini, R., Aschenbrenner, F., Berenbaum, F., D’Agostino, M.-A., Willeit, J., & Kiechl, S. (2013). Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study. Diabetes Care, 36(2), 403-409. https://doi.org/10.2337/dc12-0924

Louati, K., Vidal, C., Berenbaum, F., & Sellam, J. (2015). Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD Open, 1(1), Article e000077. https://doi.org/10.1136/rmdopen-2015-000077

Laiguillon, M.-C., Courties, A., Houard, X., Auclair, M., Sautet, A., Capeau, J., Fève, B., Berenbaum, F., & Sellam, J. (2015). Characterization of diabetic osteoarthritic cartilage and role of high glucose environment on chondrocyte activation: toward pathophysiological delineation of diabetes mellitus-related osteoarthritis. Osteoarthritis and Cartilage, 23(9), 1513-1522. https://doi.org/10.1016/j.joca.2015.04.026

Senolt, L., Braun, M., Olejárová, M., Forejtová, S., Gatterová, J., & Pavelka, K. (2005). Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein. Annals of the Rheumatic Diseases, 64(6), 886-890. https://doi.org/10.1136/ard.2004.029140

Berenbaum, F. (2012). Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. Postgraduate Medical Journal, 88(1038), 240-242. https://doi.org/10.1136/pgmj.2010.146399rep

Fedkov, D., Trush, I., & Olifirenko, O. (2013). Dysmetabolizm khriashchovoi tkanyny u khvorykh na osteoartroz: laboratorno-instrumentalna diahnostyka ta shliakhy medykamentoznoi korektsii [Cartilage dismetabolism in patients with osteoarthritis: laboratory and instrumental diagnostics and ways of its correction by medicines]. Klinichna medytsyna, (1), 80-85. [in Ukrainian].

Watt, F. E. (2018). Osteoarthritis biomarkers: year in review. Osteoarthritis and Cartilage, 26(3), 312-318. https://doi.org/10.1016/j.joca.2017.10.016

Starodubtseva, I. A., & Vasilieva, L. V. (2016). Sravnitel'nyi analiz urovnya oligomernogo matriksnogo proteina khryashcha v syvorotke krovi patsientov s zabolevaniyami kostno-myshechnoi sistemy [The comparative analysis of level of oligomeric matrix protein of cartilage in blood serum of patients with diseases of musculo-skeletal system]. Klinicheskaya laboratornaya diagnostika, 61(2), 83-86. [in Russian].

Firner, S., Zaucke, F., Heilig, J., Marées, M., Willwacher, S., Brüggemann, G., & Niehoff, A. (2020). Impact of knee joint loading on fragmentation of serum cartilage oligomeric matrix protein. Journal of Orthopaedic Research, 1-9. https://doi.org/10.1002/jor.24586

Hao, H. Q., Zhang, J. F., He, Q. Q., & Wang, Z. (2019). Cartilage oligomeric matrix protein, C-terminal cross-linking telopeptide of type II collagen, and matrix metalloproteinase-3 as biomarkers for knee and hip osteoarthritis (OA) diagnosis: a systematic review and meta-analysis. Osteoarthritis and Cartilage, 27(5), 726-736. https://doi.org/10.1016/j.joca.2018.10.009

Hoch, J. M., Mattacola, C. G., Medina McKeon, J. M., Howard, J. S., & Lattermann, C. (2011). Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis and Cartilage, 19(12), 1396-1404. https://doi.org/10.1016/j.joca.2011.09.005

Saberi Hosnijeh, F., Siebuhr, A. S., Uitterlinden, A. G., Oei, E. H. G., Hofman, A., Karsdal, M. A., Bierma-Zeinstra, S. M., Bay-Jensen, A. C., & van Meurs, J. B. J. (2016). Association between biomarkers of tissue inflammation and progression of osteoarthritis: evidence from the Rotterdam study cohort. Arthritis Research & Therapy, 18, 81. https://doi.org/10.1186/s13075-016-0976-3

Posey, K., & Hecht, J. (2008). The Role of Cartilage Oligomeric Matrix Protein (COMP) in Skeletal Disease. Current Drug Targets, 9(10), 869-877. https://doi.org/10.2174/138945008785909293

Acharya, C., Yik, J. H. N., Kishore, A., Van Dinh, V., Di Cesare, P. E., & Haudenschild, D. R. (2014). Cartilage oligomeric matrix protein and its binding partners in the cartilage extracellular matrix: Interaction, regulation and role in chondrogenesis. Matrix Biology, 37, 102-111. https://doi.org/10.1016/j.matbio.2014.06.001

Posey, K. L., Coustry, F., & Hecht, J. T. (2018). Cartilage oligomeric matrix protein: COMPopathies and beyond. Matrix Biology, 71-72, 161-173. https://doi.org/10.1016/j.matbio.2018.02.023

Al-Jarallah, K., Shehab, D., Abdella, N., Al Mohamedy, H., & Abraham, M. (2015). Knee Osteoarthritis in Type 2 Diabetes Mellitus: Does Insulin Therapy Retard Osteophyte Formation? Medical Principles and Practice, 25(1), 12-17. https://doi.org/10.1159/000441418

Sellam, J., & Berenbaum, F. (2013). Is osteoarthritis a metabolic disease? Joint Bone Spine, 80(6), 568-573. https://doi.org/10.1016/j.jbspin.2013.09.007

Robertson, F., Geddes, J., Ridley, D., McLeod, G., & Cheng, K. (2012). Patients with Type 2 diabetes mellitus have a worse functional outcome post knee arthroplasty: A matched cohort study. The Knee, 19(4), 286-289. https://doi.org/10.1016/j.knee.2011.06.001

Frey, N., Hügle, T., Jick, S. S., Meier, C. R., & Spoendlin, J. (2016). Type II diabetes mellitus and incident osteoarthritis of the hand: a population-based case–control analysis. Osteoarthritis and Cartilage, 24(9), 1535-1540. https://doi.org/10.1016/j.joca.2016.04.005

Yatsyshyn, R. I., & Sukhorebska, M. Ya. (2015). Rol biomarkeriv poshkodzhennia suhlobovoho khriashcha u diahnostytsi y otsintsi efektyvnosti likuvannia khvorykh na osteoartroz [The role of biomarkers of articular cartilage damage in the diagnosis and assessment of the effectiveness of treatment of patients with osteoarthritis]. Ukrainskyi revmatolohichnyi zhurnal, (2), 36-41. [in Ukrainian].

Downloads

How to Cite

1.
Orlenko VL, Tronko MD. Clinical and biochemical markers of joint damage in patients with diabetes mellitus. Zaporozhye Medical Journal [Internet]. 2020Jun.10 [cited 2024Dec.23];22(3). Available from: http://zmj.zsmu.edu.ua/article/view/204896

Issue

Vol. 22 No. 3 (2020)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)